Sign in
ATNM Stock Price, Chart, Stats & News
Actinium Pharmaceuticals, Inc.
Save
Actinium Pharmaceuticals, Inc. (ATNM) does not currently pay a dividend.
–
Market cap
–
Current P/E
6.84x
Forward P/E
ATNM chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | -810.00% |
Operating margin | -41486.67% |
Pretax margin | -38443.33% |
Net margin | -38443.33% |
Effective tax rate | – |
ROA | -61.62% |
ROE | -151.67% |
D/E | 0.08x |
Interest coverage ratio | – |
ATNM valuation
P/E | – |
P/S | 357.02x |
P/B | 2.33x |
P/CF | -1.28x |
P/FCF | -1.28x |
P/OCF | -1.28x |
PEG | -0.06x |
EV multiple | -2.50x |
About
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing and commercializing treatments, primarily focusing on those for bone marrow transplant (BMT) or other cellular and adoptive cell therapies. Its leading drug candidate, I-131 apamistamab (known as Iomab-B), is currently in a crucial Phase III clinical trial for its role in conditioning elderly patients with relapsed or refractory acute myeloid leukemia prior to BMT. Additionally, Iomab-B is being evaluated in a Phase I study for its use with CD19-targeted CAR T-cell therapy, a partnership with Memorial Sloan Kettering Cancer Center.
Similar securities
Based on sector and market capitalization
Report issue